Recombinetics today announced its new board of directors following this week’s completion of a $34 million Series A financing round. Gundersen Health System, a physician-led, not-for-profit healthcare system with locations in Wisconsin, Minnesota and Iowa, led the round as a strategic investor and now has three representatives on Recombinetics’ Board. [...]
Recombinetics, a pioneer in gene-editing solutions for human health and animal agriculture, today announced the completion of a $34 million Series A financing round. “We’re pleased to announce the successful completion of our Series A Round,” said Tammy Lee, President and CEO of Recombinetics. “This financing will allow us to [...]
Precision Breeding Partnership to Eliminate the Need to Dehorn Cattle Recombinetics has formed an alliance with Semex, a Canadian-based, farmer-owned cattle genetics organization, to implement a precision breeding program that improves animal health and well-being through hornless dairy cattle genetics. The dehorning of calves is a routine procedure, designed to [...]
New York-based Expertise Added for Capital Raise and Financing Strategies and Regenerative Medicine Organ Development and Transplantation Program ST. PAUL, Minn. Recombinetics (RCI), a pioneer in gene editing solutions for human health and animal agriculture, today announced two new appointments to its governance and strategic advisory boards. “The addition of [...]
Recombinetics today announced a multi-year, exclusive collaborative research and development agreement with Children’s Minnesota, the seventh largest pediatric healthcare system in the country, to produce the first-ever large animal model of Phenylketonuria (PKU). PKU is one of the most common inborn errors of metabolism with a cumulative incidence of approximately [...]
Recombinetics (RCI) announced that Dr. Mitchell Abrahamsen has joined RCI as Executive Vice President and Chief Commercial Officer. Dr. Abrahamsen will lead product and business development efforts for RCI and its subsidiaries that are commercializing gene-edited animal models for biomedical and agricultural use, Acceligen and Surrogen. Abrahamsen will also continue to [...]
Recombinetics announced the development of the first-of-their-kind gene-edited swine models for Neurofibromatosis Type 1 (NF1). Partially funded by the Children’s Tumor Foundation, and in collaboration with the University of Minnesota, these models are for use in preclinical safety and efficacy testing of therapeutics for this debilitating genetic disease affecting 1 [...]
We couldn't be prouder of our co-founder, Dr. Perry Hackett, who was recognized by his research peers at University of Minnesota's Inventor Recognition Event in the "Impact" category. This award is given to the "researcher whose innovation has most positively and most broadly impacted quality of life. The innovation's impact [...]
Recombinetics announced today that the Chinese Patent Office has issued ZL201280020439.X covering methods of making livestock with alleles from other breeds without meiotic recombination. The issued claims are not limited to a specific gene-editing tool. Specifically, the issued Chinese patent ZL201280020439.X includes a breeding method that can quickly introgress a [...]
Recombinetics is listed as a "major industry participant" in this report on Global Gene Editing Market by Global Market Insights.